32 results
8-K
EX-99.2
CNTA
Centessa Pharmaceuticals plc
10 Sep 24
Regulation FD Disclosure
7:08am
highly correlate with EEG/EMG measures (Black, et al., ESRS2022 presentation). Age at first dose was 16-20 wks in male C57BL/6J mice; mice dosed at 5
DEFA14A
CNTA
Centessa Pharmaceuticals plc
20 May 24
Additional proxy soliciting materials
8:48pm
value based on the fair value of grants under the Black-Scholes model
CEO Remuneration Table ($000)
Total Remuneration
Annual Bonus (% of maximum
PRE 14A
o78dq19y4na4n3msj
26 Apr 24
Preliminary proxy
4:36pm
8-K
EX-99.2
lnklc9zn
22 Apr 24
Regulation FD Disclosure
7:15am
8-K
EX-99.1
djd32b3 1o
25 Oct 23
Regulation FD Disclosure
9:49am
8-K
EX-99.2
pjkqa1d3wj wb
25 Oct 23
Regulation FD Disclosure
9:49am
8-K
EX-99.1
1f73p8 nvcyu0g9ow2
23 Aug 23
ORX750, an oral selective orexin receptor 2 agonist, promotes wakefulness and reduces cataplexy in the orexin/ataxin-3 mouse
6:00pm
DEF 14A
k9mcdetz
23 May 22
Definitive proxy
8:00am